NCT05507827View on ClinicalTrials.gov

Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 18, 2022

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Lymphoid Leukemia
Interventions
DRUG

Allogeneic donor-derived T-cells transduced with bivalent lentiviral vector (CD19/CD22-BBz) chimeric antigen receptor (CAR)

CD19/C22CAR T cells will be administered at a dose of CAR+ cells/kg body weight via IV administration

DRUG

Treg CD34+HSPC (Orca-T)

Purified donor-derived regulatory T-cell (Treg) plus CD34 + hematopoietic progenitor cells

Trial Locations (1)

94305

Stanford Cancer Center, Palo Alto

All Listed Sponsors
collaborator

National Marrow Donor Program

OTHER

collaborator

American Society of Hematology

OTHER

lead

Stanford University

OTHER